Search research articles
Contact Us
Filters
Showing results (11-20 of 54) with videos related to
Page
of 6
Sort By:
Clinical Laboratory Management Review : Official Publication of the Clinical Laboratory Management Association
|
December 10, 1990
Recruiting and retaining phlebotomists
B Hendrix, B Creel, H Jameson, et al.
Alzheimer'S Research & Therapy
|
May 24, 2023
Avoiding future controversies in the Alzheimer's disease space through understanding the aducanumab data and FDA review
Samuel P Dickson, Sean Hennessey, Jessie Nicodemus Johnson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Caleb W Dayley, Samuel P Dickson, Kent Hendrix, et al.
Statistics in Medicine
|
May 18, 2026
Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases
Florian Stijven, Craig Mallinckrodt, Geert Molenberghs, et al.
Neurology. Clinical Practice
|
March 9, 2023
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
Alette M Wessels, Ellen B Dennehy, Sherie A Dowsett, et al.
The Lancet. Neurology
|
November 4, 2017
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 13, 2020
36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Frontiers in Medical Technology
|
July 6, 2026
Efficacy assessment in trials of complex and rare diseases: a comparison between the meta-analytic global statistical test and co-primary analysis
Samuel P Dickson, Abe Durrant, Caleb W Dayley, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 27, 2025
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials
Samuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, et al.
The Lancet. Neurology
|
May 3, 2008
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Gordon K Wilcock, Sandra E Black, Suzanne B Hendrix, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 54) with videos related to
Sort By:
Page
of 6
Clinical Laboratory Management Review : Official Publication of the Clinical Laboratory Management Association
|
December 10, 1990
Recruiting and retaining phlebotomists
B Hendrix, B Creel, H Jameson, et al.
Alzheimer'S Research & Therapy
|
May 24, 2023
Avoiding future controversies in the Alzheimer's disease space through understanding the aducanumab data and FDA review
Samuel P Dickson, Sean Hennessey, Jessie Nicodemus Johnson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Caleb W Dayley, Samuel P Dickson, Kent Hendrix, et al.
Statistics in Medicine
|
May 18, 2026
Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases
Florian Stijven, Craig Mallinckrodt, Geert Molenberghs, et al.
Neurology. Clinical Practice
|
March 9, 2023
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
Alette M Wessels, Ellen B Dennehy, Sherie A Dowsett, et al.
The Lancet. Neurology
|
November 4, 2017
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
September 13, 2020
36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Frontiers in Medical Technology
|
July 6, 2026
Efficacy assessment in trials of complex and rare diseases: a comparison between the meta-analytic global statistical test and co-primary analysis
Samuel P Dickson, Abe Durrant, Caleb W Dayley, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 27, 2025
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials
Samuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, et al.
The Lancet. Neurology
|
May 3, 2008
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Gordon K Wilcock, Sandra E Black, Suzanne B Hendrix, et al.
Page
of 6